NAMS - NASDAQ
NewAmsterdam Pharma Company N.V.
$32.11
+0.75%NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
At a Glance
Live SnapshotNewAmsterdam Pharma Company N.V. Management Team
Michael Harvey Davidson FACC Facp.
CEO, President & Executive Director
Compensation
$1,139,142
Louise Kooij
Chief Accounting Officer
Compensation
$695,419
Marc Ditmarsch
Chief Development Officer
Mayur Amrat Somaiya
Chief Financial Officer
Compensation
$770,393
Michael F. Marino
Chief Legal Officer & Corporate Secretary
Douglas F. Kling
Chief Operating Officer
Compensation
$790,051
Maryellen McQuade
Chief People Officer
Juliette Audet
Chief Strategy & Business Officer
Compensation
$653,039
Matthew Philippe
Executive VP & Head of Investor Relations
Bob Rambo
Executive Vice President of Marketing
Chris Deluzio
Executive Vice President of Sales Enterprise Operations
Johannes Jacob Pieter Kastelein FESC
Founder, Chief Scientific Officer, Member of Executive Board & Director
Compensation
$808,143
NewAmsterdam Pharma Company N.V. Insider Positioning
During the last 12 months, insiders have sold $3.66M worth of NAMS shares, with no buying activity reported.
3 Months
0
0.00
109.2K
3.66M
-3.7M
-$3.66M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Kooij Louise Frederika
Officer: Chief Accounting Officer
$2.32M
Lange Louis G
Director
$1.34M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $3.66M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
SEC Filings
NAMS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | May 08, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 09, 2024 | June 05, 2024 | 2024 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.